Product Search:
 
 

 

 
CELPROGEN
is a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, Invitro diagnostics and academic partnership for drug discovery.

  

   The Therapeutics Division

     The Life Science Division      The Device Division
  
 Has focused its Drug Discovery efforts in the development of Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Renal and Metabolic disorders.
 
 
 
   
    
 Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for  life science academic and pharmaceutical communities.

 
   
 Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and Invitro diagnostics Indutstries.
 
 
 
 
   

Calcium Ratio Measurement of Cardiomiocyte in Culture - 3D Video


Click to view

................................................................................................................

  Mouse Endothelial Cells in 3D Video Clip


Click to view

................................................................................................................

  Cardiomyocyte 10x Day 9 Video Clip


Click to view

 

  
  

     
The therapeutic pipeline consists of the following drug development projects in their pre-clinical phase of development:
 

  » CPG23CARD - Cholesterol lowering agent/drug.
 

 
» CPG23DIAB - Glucose lowering agent/drug for Type 1&2 diabetes.
 

 
» CPG23STEM - Adult stem cells that were trans-differentiated to β-Islets of Langerhan Cells to produce insulin. Pre-clinical invitro data has great promise for cellular based therapeutics for Type 1 diabetes.
 

 
» CPG23NEUR - Adult stem cells that were trans-differentiated to neuronal cells, pre-clinical invitro data has promise for cellular based therapeutics for neurologial disorders.
 

 
» CPG23PANC - Dendritic cell/peptide vaccine for pancreatic cancer

 
   
© Copyright 2007 -2009 Celprogen, Inc. All rights reserved.

Privacy Policy